We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · February 16, 2021

Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists

JACC: Heart Failure


Additional Info

JACC: Heart Failure
Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF
JACC Heart Fail 2021 Jan 28;[EPub Ahead of Print], L Shen, SL Kristensen, O Bengtsson, M Böhm, RA de Boer, KF Docherty, SE Inzucchi, T Katova, L Køber, MN Kosiborod, AM Langkilde, D Lindholm, MFA Martinez, E O'Meara, JC Nicolau, MC Petrie, P Ponikowski, MS Sabatine, M Schou, M Sjöstrand, SD Solomon, PS Jhund, JJV McMurray

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading